Orion Entered into a Research Collaboration with Peptilogics to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target

Shots:

The collaboration will combine Peptilogics’ Nautilus AI-driven peptide design platform with Orion’s GPCR platform for drug discovery against an undrugged peptidergic GPCR to treat prevalent, life-threatening diseases
Peptilogics use its Nautilus platform to create multiparameter-optimized peptides with the ability to target both novel and historically difficult therapeutic targets by combining deep generative algorithms, predictive models, and biophysical simulation
Orion’s platform explores the receptor-ligand shape space to produce precision-engineered peptides with increased potency and specialized signaling activity by utilizing patented multiplex synthesis technology

Ref: GlobalNewswire | Image: Orion